French laboratory Sanofi, repeatedly criticized for its delay in the coronavirus vaccination race, has announced that its vaccine should be available in December.
Composed of recombinant protein, it is currently in the phase of massive trials.
A second vaccine using messenger RNA technology is also in development.
The vaccine against Covid-19 developed by the French laboratory Sanofi, in collaboration with the British GSK, should be available in December, said the French president of the laboratory, Monday.
Asked about France Inter on the availability of this recombinant protein-based vaccine - a technology already used by Sanofi for one of its influenza vaccines - Olivier Bogillot confirmed that he would be ready in "December actually".
The group had previously indicated to count on the fourth quarter, then specified to envisage a provision by the end of the year.
This vaccine, now in the phase of massive trials, called phase 3, had been delayed by several months, causing controversy.
A second messenger RNA vaccine
At the same time, Sanofi is developing another vaccine against Covid, based on messenger RNA technology, with an American partner, the startup Translate Bio. They have started the first clinical trials which should give their results in the third trimester. These are already messenger RNA vaccines that were among the first to be distributed in early 2021 against Covid-19, those of Pfizer and Moderna.